MARKET

TPST

TPST

Tempest Therapeutics Inc
NASDAQ
1.270
0.000
0.00%
After Hours: 1.250 -0.02 -1.57% 19:58 06/09 EDT
OPEN
1.240
PREV CLOSE
1.270
HIGH
1.290
LOW
1.240
VOLUME
72.97K
TURNOVER
--
52 WEEK HIGH
12.23
52 WEEK LOW
1.230
MARKET CAP
18.80M
P/E (TTM)
-0.2044
1D
5D
1M
3M
1Y
5Y
1D
Tempest Therapeutics director William Drake Richey files initial beneficial ownership statement
PUBT · 1d ago
Weekly Report: what happened at TPST last week (0601-0605)?
Weekly Report · 2d ago
Tempest Therapeutics Announces CFO Transition and Board Changes
TipRanks · 5d ago
Tempest Therapeutics Nicholas Maestas Resigns As CFO Effective June 5, 2026; Appoints Justin Trojanowski As Principal Financial Officer Effective June 5, 2026
Benzinga · 5d ago
TEMPEST THERAPEUTICS - APPOINTS JUSTIN TROJANOWSKI AS PRINCIPAL FINANCIAL OFFICER EFFECTIVE JUNE 5, 2026 - SEC FILING
Reuters · 5d ago
Tempest Therapeutics adds Drake Richey, John Yee to board
PUBT · 5d ago
TEMPEST THERAPEUTICS APPOINTS DRAKE RICHEY AND JOHN YEE, MD, MPH TO BOARD OF DIRECTORS
Reuters · 5d ago
Press Release: Tempest Therapeutics Appoints Drake Richey and John Yee, MD, MPH to Board of Directors
Dow Jones · 5d ago
More
About TPST
Tempest Therapeutics, Inc. is a clinical-stage biotechnology company moving towards late-stage development with a portfolio of targeted and immune-mediated product candidates with the potential to be first-in-class to treat a range of cancers. Its programs range from early research to the lead program, amezalpat, a pivotal study in first-line hepatocellular carcinoma (HCC). Its second clinical program, TPST-1495, is a novel, small-molecule dual antagonist of the EP2 and EP4 receptors of prostaglandin E2 (PGE2), a pathway implicated in multiple cancers. Its development strategy for TPST-1495 includes evaluation in familial adenomatous polyposis (FAP), a rare genetic disorder that increases the risk of gastrointestinal cancers. Its pipeline also includes TPST-2003, TPST-2206, TPST-3003, and TPST-3206. TPST-2003 is a new dual-targeting CD19/BCMA CAR-T asset. TPST-2206 is a dual-targeting CD70/CD70 CAR-T for renal cell carcinoma. TPST-3206 is an allogeneic dual-targeting CD70/CD70.

Webull offers Tempest Therapeutics Inc stock information, including NASDAQ: TPST real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, TPST stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading TPST stock methods without spending real money on the virtual paper trading platform.